

#### DESCRIPTION

**Source** *Spodoptera frugiperda*, Sf 21 (baculovirus)-derived mouse CX3CL1/Fractalkine protein  
Gln25-Arg337, with a C-terminal 6-His tag  
Accession # O35188

**N-terminal Sequence Analysis** No results obtained: Gln25 predicted

**Predicted Molecular Mass** 34 kDa

#### SPECIFICATIONS

**SDS-PAGE** 90 kDa, reducing conditions

**Activity** Measured by its ability to chemoattract freshly isolated human peripheral blood lymphocytes (PBL).  
The ED<sub>50</sub> for this effect is 0.2-0.6 µg/mL.

Measured by its ability to chemoattract BaF3 mouse pro-B cells transfected with mouse CX3CR1.  
The ED<sub>50</sub> for this effect is 0.03-0.12 µg/mL.

**Endotoxin Level** <0.10 EU per 1 µg of the protein by the LAL method.

**Purity** >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.

**Formulation** Lyophilized from a 0.2 µm filtered solution in PBS with BSA as a carrier protein. See Certificate of Analysis for details.

#### PREPARATION AND STORAGE

**Reconstitution** Reconstitute at 100 µg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.

**Shipping** The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

**Stability & Storage** **Use a manual defrost freezer and avoid repeated freeze-thaw cycles.**

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

#### BACKGROUND

Fractalkine, designated CX3CL1 and also known as neurotactin, is the only member of the CX3C, or delta, chemokine subfamily (1 - 4). Unlike most other chemokines, CX3CL1 is a type I transmembrane (TM) adhesion protein (1). The mouse CX3CL1 cDNA encodes 395 amino acids (aa), including a signal sequence (aa 1 - 24), a chemokine domain (aa 25 - 100), a mucin stalk region (aa 101 - 336), a transmembrane segment (aa 337 - 357), and a cytoplasmic tail (aa 358 - 395). The chemokine domain contains binding and chemotactic determinants, while the mucin stalk appears to function only as a spacer (4, 5). Mouse CX3CL1 shares 85% and 78% aa sequence identity with rat and human CX3CL1, respectively, within the chemokine domain, but lower sequence identity within other domains. CX3CL1 is up-regulated by pro-inflammatory stimuli, especially IFN-γ and TNF-α, on cell types including macrophages, dendritic cells, endothelium, neurons, smooth muscle and epithelium lining the intestines and other tubules (1, 8, 9). The 40 kDa, 7-TM non-glycosylated G-protein coupled CX3CL1 receptor, CX3CR1, is expressed by cytotoxic effector cells and cytokine producers, including type I helper and cytotoxic T cells, γδ T cells, CD16+ NK cells, monocytes and microglia (1, 2). The 95 - 100 kDa TM CX3CL1 can be inducibly cleaved near the TM segment by ADAM10 or ADAM17 to generate a 60 - 80 kDa soluble form (6, 7). TM CX3CL1 functions as an adhesion molecule, while both forms are chemoattractants for target cells expressing CX3CR1 (1, 2). During extravasation, membrane-bound CX3CL1 traps leukocytes, then is cleaved to allow diapedesis (6). In coronary artery disease, soluble CX3CL1 and CD8+ T cell CX3CR1 are overexpressed and appear to contribute to pathogenesis (1, 10). In the brain, CX3CL1/CX3CR1 interaction protects against microglial neurotoxicity (11). CX3CL1 also contributes to wound healing by recruiting macrophages, and to bone resorption by recruiting and mediating adhesion of osteoclast precursors (12, 13).

#### References:

1. Stievano, L. *et al.* (2004) *Crit. Rev. Immunol.* **24**:205.
2. Umehara, H. *et al.* (2004) *Arterioscler. Thromb. Vasc. Biol.* **24**:34.
3. Rossi, D.L. *et al.* (1998) *Genomics* **47**:163.
4. Mizoue, L.S. *et al.* (2001) *J. Biol. Chem.* **276**:33906.
5. Harrison, J.K. *et al.* (2001) *J. Biol. Chem.* **276**:21632.
6. Hundhausen, C. *et al.* (2007) *J. Immunol.* **178**:8064.
7. Tsou, C. *et al.* (2001) *J. Biol. Chem.* **276**:44622.
8. Tarozzo, G. *et al.* (2003) *J. Neurosci. Res.* **73**:81.
9. Lucas, A.D. *et al.* (2001) *Am. J. Pathol.* **158**:855.
10. Damas, J.K. *et al.* (2005) *Arterioscler. Thromb. Vasc. Biol.* **25**:2567.
11. Cardona, A.E. *et al.* (2006) *Nat. Neurosci.* **9**:917.
12. Koizumi, K. *et al.* (2009) *J. Immunol.* **183**:7825.
13. Ishida, Y. *et al.* (2008) *J. Immunol.* **180**:569.